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Abstract
Background: Human epidermal growth-factor receptor (HER)-2 is overexpressed in 25 % of breast-cancers and is
associated with an aggressive form of the disease with significantly shortened disease free and overall survival. In
recent years, the use of HER2-targeted therapies, monoclonal-antibodies and small molecule tyrosine-kinase
inhibitors has significantly improved the clinical outcome for HER2-positive breast-cancer patients. However, only
a fraction of HER2-amplified patients will respond to therapy and the use of these treatments is often limited by
tumour drug insensitivity or resistance and drug toxicities. Currently there is no way to identify likely responders or
rational combinations with the potential to improve HER2-focussed treatment outcome.
Methods: In order to further understand the molecular mechanisms of treatment-response with HER2-inhibitors,
we used a highly-optimised and reproducible quantitative label-free LC-MS strategy to characterize the proteomes
of HER2-overexpressing breast-cancer cell-lines (SKBR3, BT474 and HCC1954) in response to drug-treatment with
HER2-inhibitors (lapatinib, neratinib or afatinib).
Results: Following 12 hours treatment with different HER2-inhibitors in the BT474 cell-line; compared to the
untreated cells, 16 proteins changed significantly in abundance following lapatinib treatment (1 μM), 21 proteins
changed significantly following neratinib treatment (150 nM) and 38 proteins changed significantly following
afatinib treatment (150 nM). Whereas following 24 hours treatment with neratinib (200 nM) 46 proteins changed
significantly in abundance in the HCC1954 cell-line and 23 proteins in the SKBR3 cell-line compared to the
untreated cells. Analysing the data we found that, proteins like trifunctional-enzyme subunit-alpha, mitochondrial;
heterogeneous nuclear ribonucleoprotein-R and lamina-associated polypeptide 2, isoform alpha were up-regulated
whereas heat shock cognate 71 kDa protein was down-regulated in 3 or more comparisons.
Conclusion: This proteomic study highlights several proteins that are closely associated with early HER2-inhibitor
response and will provide a valuable resource for further investigation of ways to improve efficacy of breast-cancer
treatment.
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Background
Breast cancer remains a leading cause of death among
women in the Western World. Epidermal growth factor
receptor 2 (HER2)-gene amplification or overexpression
occurs in approximately 25 % of breast cancers and is
associated with poor prognosis [1]. Tyrosine kinases play
a critical role in the modulation of growth factor signal-
ling and activated forms of these enzymes plays a crucial
role in breast cancer pathogenesis [2]. In spite of the
efforts that are underway to develop and improve HER-
targeted therapies, de novo and acquired resistance re-
main major obstacles in the clinic; therefore, new drug
treatments and methods of accurately predicting drug
sensitivity are urgently needed [3].
Lapatinib, neratinib and afatinib are tyrosine kinase
inhibitors of HER2 and EGFR (epidermal growth factor
receptor) growth factor receptors which prevent the ac-
tivation of the receptor tyrosine kinase, inhibiting the
activation of the pathways that would promote tumour
cell growth and proliferation [4]. Lapatinib is an orally ac-
tive small molecule, it is a first-generation dual tyrosine
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kinase inhibitors that reversibly binds EGFR and HER2 [5]
that has been approved in combination with capecitabine
for the treatment of refractory breast cancer [6]. Although
lapatinib does not cross the blood–brain barrier, it can
reach therapeutic levels in brain tumours and brain me-
tastases [7]. Neratinib and afatinib, two second-generation
tyrosine kinase inhibitors that irreversibly bind to multiple
HER receptors, are being investigated in clinical trials with
promising results either as monotherapy or in combin-
ation [8, 9]. Both neratinib and afatinib have the ability to
penetrate the blood–brain barrier and, as seen also with
lapatinib, these small molecule tyrosine kinase inhibitors
have minimal adverse effects on the heart [10].
Proteomics has great potentiality to guide the discovery
of biomarkers with clinical utility for the diagnosis, treat-
ment and management of breast cancer. Indeed, the identi-
fication of proteins that are differentially expressed as result
of exposure to drug treatments such as lapatinib, neratinib
and afatinib may provide novel drug targets for improved
therapeutic action, and/or predict therapeutic outcome
[11]. Mass-spectrometry based proteomics methods, such
as label-free LC-MS (liquid chromatography-mass spec-
trometry), have become more popular for analysing quan-
titative changes in protein expression between samples
[12, 13] though there is a lack of studies investigating the
proteomic profile of lapatinib, neratinib or afatinib
response in breast cancer.
To identify markers which might be useful in predicting
treatment response and/or potential targets for rational
additional drug treatments for increasing efficacy, a sys-
tematic approach is required. Difficulties in studying
hydrophobic proteins or proteins with low or high mo-
lecular weights are common inherent proteomic chal-
lenges [14]. A method like label-free LC-MS proteomic is
ideal for such analyses as it is less impacted by many of
these limitations [12, 13]. In this study we have used a
quantitative label-free LC-MS proteomic approach to
characterize the proteomes of cell line models of HER2-
inhibitor response in HER2-positive breast cancer cell
lines models, SKBR3, BT474 and HCC1954, in order to
further understand the molecular contributors to treat-
ment response.
Methods
Cell culture and drug treatment
HER2-overexpressing breast cancer cell lines BT474,
SKBR3 and HCC1954 were examined. The BT474 cell
line was maintained in antibiotic-free Dulbeccos Modified
Eagles medium (DMEM) supplemented with 10 % fetal
bovine serum (PAA Labs, Austria), 2 % L-glutamine
(Sigma-Aldrich, Germany) and 1 % sodium pyruvate
(Sigma-Aldrich, Germany). SKBR3 and HCC1954 breast
cancer cell lines were maintained in Roswell Park Memor-
ial Institute (RPMI) 1640 medium supplemented with
10 % fetal bovine serum (PAA Labs, Austria). All cell lines
were kept at 37 °C in 5 % CO2/95 % air humidified incu-
bators. Biological replicates, for each cell line, were within
10 passages of each other. All cultures were tested rou-
tinely and were mycoplasma-free.
Drug treatments were prepared in dimethyl sulfoxide
[(DMSO) Sigma-Aldrich, Germany] at a final concentra-
tion of 0.03 % (v/v) and applied as follows lapatinib 1 μM
(Sequoia Sciences, Saint Louis, MO, USA), 150 nM afati-
nib (Sequoia Sciences, Saint Louis, MO, USA) and 150
nM or 200 nM neratinib (Sequoia Sciences, Saint Louis,
MO, USA) for 12 or 24 hours of exposure. The drug treat-
ment control consisted of the same cell line treated with
the same amount of DMSO used to dilute the drug and
for the same exposure time (12 or 24 hours). Three or
four biological samples were prepared for each cell lines.
Protein extraction
Due to the inherent variability of protein fractionation, it
was decided to analyse whole cell lysates to minimise
differences between the multiple cell lines analysed.
After 12 or 24 hours of drug exposure, cells were har-
vested for LC-MS analysis, following five washes in cold
phosphate-buffered saline (PBS) by scraping into cold
PBS. Approximately 3 × 106 cells were centrifuged at
200 g and the cell pellet snap frozen in liquid nitrogen.
Sample preparation for label-free LC-MS analysis
Cell pellets were lysed with lysis buffer {7 M Urea, 2 M
Thiourea, 30 mM Tris, 4 % 3-[(3-cholamidopropyl)di-
methylamonio]-1-propanesulfonate (CHAPS); pH 8.5}
(Sigma-Aldrich, Germany) and then were cleaned up using
the Ready Prep 2-D clean up kit (Bio-Rad, Hercules, CA,
USA). Protein concentration was determined using the
Quick Start Bradford assay (Bio-Rad, Hercules, CA, USA).
Ten micrograms of protein sample were resuspended in
40 μl of 50 mM ammonium bicarbonate (Sigma-Aldrich,
Germany). Reduction was performed by adding to the
samples an amount of dithiothreitol (DTT) (0.5 M)
(Sigma-Aldrich, Germany) to reach the concentration of
10 mM at 56 °C for 20 min, and allowed to cool to room
temperature. Samples were alkylated by adding to the sam-
ples an amount of iodoacetamide (0.55 M) (Sigma-Aldrich,
Germany) to reach the concentration of 55 mM and then
incubated for 15 min in the dark at room temperature. Di-
gestion with Trypsin Gold, Mass Spectrometry Grade
(Promega, Madison, NJ, USA) was carried out at a ratio
of 1:19 (Trypsin/Protein) at 37 °C overnight. To stop
the digestion, trifluoroacetic acid (TFA) (Sigma-Aldrich,
Germany) was add to the samples (0.5 % final concen-
tration) at 37 °C for 15 min. Samples were then cleaned
up using Pierce C18 Spin Columns (Thermo Fisher Scien-
tific, USA), dried under a vacuum and stored at −20 °C.
Prior to mass spectrometry analysis dried peptides were
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resuspended in 50 μl of 0.1 % formic acid (FA) in 2 %
acetonitrile (ACN) (Sigma-Aldrich, Germany), vortexed to
ensure an even suspension.
Mass spectrometry using LC-MS/MS
Nano LC-MS/MS analysis was carried out using an
Ultimate 3000 nanoLC system (Dionex, USA) coupled to
a hybrid linear ion trap/Orbitrap mass spectrometer (LTQ
Orbitrap XL; Thermo Fisher Scientific, USA). Five μl of
digest were loaded onto a C18 trap column (C18 PepMap,
300 m ID × 5 mm, 5 μm particle size, 100 Å pore size;
Dionex, USA) and desalted for 10 min using a flow rate of
25 μl/min in 0.1 % TFA in 2 % ACN. The trap column
was then switched online with the analytical column
[PepMap C18, 75 μm ID × 500 mm, 3 μm particle and
100 Å pore size; (Dionex, USA)] and peptides were
eluted with the following binary gradients of solvent A
and B: 0–25 % solvent B in 240 min and 25–50 % solvent
B in a further 60 min, where solvent A consisted of
2 % ACN and 0.1 % formic acid in water and solvent
B consisted of 80 % ACN and 0.08 % formic acid in
water. Column flow rate was set to 350 nl/min. Data
were acquired in data-dependent mode and externally
calibrated with Xcalibur software, version 2.0.7
(Thermo Fisher Scientific, USA). Survey MS scans
were acquired in the Orbitrap in the 400–1800 m/z
(mass-to-charge ratio) range with the resolution set to
a value of 30000 at m/z 400. Up to three of the most
intense multiply charged ions (1+, 2+ and 3+) per
scan were collision-induced dissociation (CID) frag-
mented in the linear ion trap. A dynamic exclusion
window was applied within 40 s. All tandem mass
spectra were collected using a normalised collision
energy of 35 %, an isolation window of 3 m/z, and
one microscan.
Label-free LC-MS quantitative profiling
Label-free LC-MS analysis was carried out using Progenesis
QI for proteomics software version 4.1 (NonLinear
Dynamics, UK), as recommended by the manufacturer
(see www.nonlinear.com for further background to align-
ment, normalisation, calculation of peptide abundance,
etc.). As already described by Meleady et al. [15] the soft-
ware processed the raw data in two steps. Firstly each
sample run was subjected to alignment which involved
aligning the data based on the LC retention time of each
sample; this allows for any drift in retention time giving
an adjusted retention time for all runs in the analysis. The
sample run that yielded most features (i.e. peptide ions)
was used as the reference run, to which retention time of
all of the other runs were aligned and peak intensities
were normalised. The Progenesis peptide quantification
algorithm calculates peptide abundance as the sum of the
peak areas within its isotope boundaries. Each abundance
value is then transformed to a normalised abundance
value by applying a global scaling factor. Protein abun-
dance was calculated as the sum of the abundances of all
peptide ions which have been identified as coming from
the same protein. A number of criteria were used to filter
the data before exporting the MS/MS output files to
MASCOT (www.matrixscience.com) for protein identifi-
cation; peptide features with ANOVA (analysis of vari-
ance) p-value ≤0.05 between experimental groups, mass
peaks (features) with charge states from +1 to +3, and
greater than 3 isotopes per peptide. All MS/MS spectra
were exported from Progenesis software as a MASCOT
generic file (mgf) and used for peptide identification with
MASCOT (version 2.3) searched against the UniProtKB–
SwissProt database (taxonomy, homo sapiens). The search
parameters used were as follows: peptide mass tolerance
set to 20 ppm, MS/MS mass tolerance set at 0.6 Da; up to
two missed cleavages were allowed, carbamidomethylation
set as a fixed modification and methionine oxidation set
as a variable modification. Only peptides with ion scores
of 40 and above were considered and re-imported back
into Progenesis QI for proteomics software for further
analysis. A number of criteria were applied to assign a
protein as identified; proteins with ≥2 peptides matched,
a ≥1.5 fold difference in abundance and an ANOVA be-
tween experimental groups of ≤0.05.
The biological function of the proteins identified was
assigned using ontology tools in PANTHER [16].
Results
The different concentrations employed for the three dif-
ferent drug treatments (afatinib, neratinib or lapatinib)
were chosen to reflect published clinically relevant con-
centrations [5, 17, 18]. As the aim of the current study
was to investigate proteins that are closely associated
with early treatment response and, as a short time
(12 hours) exposure to drug treatments may allow iden-
tification of a proportionally small number of proteins
that are associated with drugs response, another time
point (24 hours) and a higher drug concentration were
used to ensure that the proteins identified had a higher
likelihood of a real association with drug response.
Proteomic analysis of the HER2-overexpressing breast
cancer cell lines
Label-free proteomic analysis was performed in HER2-
overexpressing breast cancer cell lines to reveal the pro-
teins that were significantly different in the BT474 cell line
in response to afatinib, neratinib or lapatinib treatments
and also in the breast cancer cell lines SKBR3 and
HCC1954 in response to neratinib treatments. Following
analysis of the phenotypes using the software incorporated
in Progenesis QI for proteomics, all proteins were ranked
by p value derived from one-way ANOVA (p ≤ 0.05), fold
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change (≥1.5) and number of peptides (≥2) matched to
the protein.
38 significant (p ≤ 0.05) proteins whose abundance
changed significantly in the BT474 between afatinib-
treated and control cells were identified. Of these, 16
demonstrated an increased abundance (Table 1a) and 22
a decreased abundance in the treated cells (Table 1b).
Details of the significant variation between phenotypes
are presented in Table 1. 21 and 16 proteins differed in
abundance respectively between the BT474 cell lines
neratinib or lapatinib-treated compared to untreated
cells (Tables 2 and 3). In the comparison with the nerati-
nib treated cell lines 18 proteins demonstrated an in-
creased abundance (Table 2a) and three a decreased
abundance in the treated cells (Table 2b). Of the 16 pro-
teins identified in the comparison with the lapatinib
treated cell lines 11 proteins demonstrated an increased
abundance (Table 3a) and five a decreased abundance in
the treated cells (Table 3b). Figure 1 show a Venn dia-
gram highlighting the proteins that were in common
between the proteins that were significantly different in
the BT474 cell line in response to afatinib, neratinib or
lapatinib treatments. The diagrams shows that 33, ten
and eight proteins identified respectively in afatinib, ner-
atinib or lapatinib treated cell line were unique in each
comparison. Two proteins were common among all
three comparisons, three and six were in common re-
spectively between afatinib and neratinib and between
neratinib and lapatinib-treated cells. There were no pro-
teins common between afatinib and lapatinib-treated
cells.
23 proteins were observed to vary significantly (p ≤ 0.05)
in abundance between the SKBR3 cell line neratinib-
treated compared to untreated cells (Table 4). Out of these
23 proteins, 17 demonstrated an increased abundance
(Table 4a) and six a decreased abundance in the treated
cells (Table 4b).
46 proteins were observed to vary significantly (p ≤ 0.05)
in abundance between the HCC1954 cell line neratinib-
treated compared to untreated cells (Table 5). Of these, 22
demonstrated an increased abundance (Table 5a) and 24 a
decreased abundance in the treated cells (Table 5b).
Figure 2 show a Venn diagram highlighting the pro-
teins that were in common between the proteins that
were significantly different in the three different cell
lines (BT474, HCC1954 or SKBR3) in response to nera-
tinib treatments. The diagrams shows that 18, 42 and
18 proteins identified respectively in BT474, HCC1954
or SKBR3 treated cell line were unique in each com-
parison. There were no proteins in common in all three
comparisons. One, three and two proteins were in com-
mon respectively between BT474 and HCC1954, be-
tween HCC1954 and SKBR3 and between BT474 and
SKBR3 neratinib treated cell lines.
Following label-free proteomic analysis 194 and 228
proteins were observed to vary significantly (p ≤ 0.05) in
abundance respectively between SKBR3 and HCC1954
cell lines or between SKBR3 and HCC1954 cell lines
both treated with neratinib. 123 were in common be-
tween the two comparisons. In the comparison between
SKBR3 and HCC1954 cell lines 104 proteins demon-
strated an increased abundance and 90 a decreased
abundance in HCC1954 cell line. Of the 228 proteins
identified in the comparisons between SKBR3 and
HCC1954 cell lines both treated with neratinib 105 pro-
teins demonstrated an increased abundance and 123 a
decreased abundance in HCC1954 cell line treated with
neratinib.
Table 6 shows a list of 17 proteins that were identified in
more than one comparisons between the identified proteins
with altered levels in response to afatinib, lapatinib or nera-
tinib treatment compared to control in BT474 cell line and
also in neratinib treatment compared to control in
HCC1954 and SKBR3 cell lines. There were no proteins in
common in all five comparisons. Trifunctional enzyme
subunit alpha, mitochondrial was in common and up-
regulated among four comparison whereas, heterogeneous
nuclear ribonucleoprotein R and lamina-associated poly-
peptide 2, isoform alpha were in common and up-regulated
between three comparisons. 11 proteins are in common be-
tween two comparisons, of these eight were up-regulated
and three down-regulated among comparisons. Moreover,
three proteins showed an irregular abundance pattern in
response to different drugs treatment and/or cell line, phos-
phoglycerate kinase 1 was down-regulated in response to
afatinib in BT474 cell line and in response to neratinib in
HCC1954 cell line, but was up-regulated in response to
neratinib in SKBR3 cell line. Ubiquitin-like modifier-
activating enzyme 1 and heterogeneous nuclear ribonucleo-
protein Q showed both an opposite abundance pattern in
response to afatinib in BT474 cell line and in response to
neratinib in HCC1954 cell line. Details are presented in
Table 6.
Discussion
Despite the improvements in diagnosis and treatment of
breast cancer, novel and more efficient tools are needed
to guide diagnosis and individualise therapy to improve
patient-outcomes and overall survival-rates [19]. In this
study, we used label-free LC-MS proteomics to identify
proteins associated with HER2-inhibitor drugs response
in HER2-positive cell lines. To achieve this we charac-
terised the proteomic response of three HER2-targeting
tyrosine kinase inhibitors (lapatinib, neratinib and afati-
nib) in the overexpressing HER2 BT474 cell line. In
addition, because of the complexity of breast cancer and
to get a broader perspective in multiple breast cancer
cell lines, we characterised the proteomic response to
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Table 1 38 proteins identified as differentially expressed between the afatinib treated BT474 cell line and the control following
label-free MS/MS analysis (Progenesis QI for proteomics)






O14979;Q14103 Heterogeneous nuclear ribonucleoprotein D-like 4 216.49 0.000367 2.37 Afatinib
Q00839 Heterogeneous nuclear ribonucleoprotein U 3 151.34 0.001436 1.61 Afatinib
P31943 Heterogeneous nuclear ribonucleoprotein H 2 140.67 0.002201 1.58 Afatinib
P40939 Trifunctional enzyme subunit alpha, mitochondrial 2 190.67 0.007201 2.05 Afatinib
Q9Y2X3 Nucleolar protein 58 2 114.49 0.008894 1.86 Afatinib
Q09666 Neuroblast differentiation-associated protein AHNAK 2 90.42 0.008936 1.56 Afatinib
Q8NBS9 Thioredoxin domain-containing protein 5 2 110.22 0.013371 1.56 Afatinib
Q12906 Interleukin enhancer-binding factor 3 2 133.56 0.015709 1.62 Afatinib
P68431 Histone H3.1 2 199.81 0.019319 1.61 Afatinib
P55084 Trifunctional enzyme subunit beta, mitochondrial 1 146.98 0.023507 1.6 Afatinib
O60506 Heterogeneous nuclear ribonucleoprotein Q 1 187.85 0.024443 2.81 Afatinib
P10809 60 kDa heat shock protein, mitochondrial 2 132.64 0.026205 5.23 Afatinib
P09429 High mobility group protein B1 1 140.79 0.027432 1.58 Afatinib
P62937 Peptidyl-prolyl cis-trans isomerase A 3 193.48 0.034894 1.75 Afatinib
A6NMY6 Putative annexin A2-like protein 2 127.79 0.03901 1.69 Afatinib
O43390 Heterogeneous nuclear ribonucleoprotein R 1 217.31 0.049038 2.27 Afatinib
b
P08133 Annexin A6 2 88.25 0.004506 1.61 Control
A6NEC2 Puromycin-sensitive aminopeptidase-like protein 2 114.96 0.004836 1.75 Control
P48735 Isocitrate dehydrogenase [NADP], mitochondrial 2 100.11 0.005263 1.65 Control
P15531 Nucleoside diphosphate kinase A 2 116.29 0.005349 2.05 Control
P12268 Inosine-5'-monophosphate dehydrogenase 2 2 123.5 0.007421 1.52 Control
P22314 Ubiquitin-like modifier-activating enzyme 1 3 162.89 0.00852 1.58 Control
P00558 Phosphoglycerate kinase 1 3 135.58 0.008782 1.62 Control
P11216 Glycogen phosphorylase, brain form 2 97.04 0.009668 1.67 Control
P61204 ADP-ribosylation factor 3 2 190.14 0.010494 1.64 Control
P50570;Q05193 Dynamin-2 2 115.29 0.011594 1.99 Control
P21796;Q9Y277 Voltage-dependent anion-selective channel protein 1 3 215.59 0.014497 1.58 Control
Q9Y5B9 FACT complex subunit SPT16 2 114.74 0.014521 2.14 Control
P07384 Calpain-1 catalytic subunit 5 261.15 0.015632 1.59 Control
P50395 Rab GDP dissociation inhibitor beta 4 193.14 0.016052 1.55 Control
O43776 Asparagine–tRNA ligase, cytoplasmic 2 84.46 0.019422 1.56 Control
Q14566 DNA replication licensing factor MCM6 3 153.97 0.022003 1.59 Control
P35579 Myosin-9 3 153.68 0.02416 1.68 Control
P49189 4-trimethylaminobutyraldehyde dehydrogenase 2 108.57 0.027635 1.56 Control
Q86VP6 Cullin-associated NEDD8-dissociated protein 1 2 100.91 0.029028 1.67 Control
P04792 Heat shock protein beta-1 3 162.14 0.032666 1.73 Control
P31948 Stress-induced-phosphoprotein 1 2 102.57 0.032815 1.84 Control
Q9NUU7 ATP-dependent RNA helicase DDX19A 2 128.15 0.042435 1.72 Control
16 proteins were up regulated in the cells treated with afatinib (Table 1a) and 22 proteins were up regulated in the untreated cells (control) (Table 1b). *) Accession
number in the UniProt database; †) Peptides used for quantitation; ‡) MASCOT score. §) Indicates if the proteins were up regulated in the treated cells (afatinib) or in
the not treated cells (control)
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neratinib treatment in two other overexpressing HER2
cell lines (HCC1954 and SKBR3). The different concen-
trations employed for the three different drug treatments
represented the typical pharmacokinetic trough concentra-
tion that has been reported from patient trials [5, 17, 18].
This approach allowed us to identify a short list of 14 pro-
teins whose expression level alters with a similar abundance
patterns between different comparisons (11 up-regulated
and three down-regulated) and that appear to be strongly
involved in early treatment response.
Breast cancer cell lines have been widely used to investi-
gate different aspect of the disease, generating reprodu-
cible and quantifiable results [20], although several
problems may arise when using such models. Firstly, pro-
tein expression may differ from cell line to cell line within
a single organism [21]. In our study, a high number of
proteins (194) were shown to change significantly in abun-
dance between SKBR3 and HCC1954 cell lines. Secondly,
no single cell line is truly representative of a primary
breast cancer, however, when a panel of cell lines are used
as a system they can provide powerful information [22].
This study highlighted several proteins (in the three differ-
ent cell lines) that had altered abundance in response to
neratinib treatment, namely, trifunctional enzyme subunit
alpha, mitochondrial; lamina-associated polypeptide 2,
isoform alpha; carnitine O-palmitoyltransferase 1, liver
isoform and 6-phosphogluconate dehydrogenase, decarb-
oxylating. These proteins are generally involved in the
fatty acid metabolism and glycolysis and were up-
regulated in response to the drug treatment. Heat shock
cognate 71 kDa protein that is involved in stress response
was down-regulated in response to neratinib treatment.
These proteins were in common between BT474 and
SKBR3, between BT474 and HCC1954 or between SKBR3
and HCC1954.
In the current study, we also investigated the protein re-
sponse to lapatinib, neratinib or afatinib, emerging HER2-
inhibitor in BT474 cell lines. Interestingly, trifunctional
enzyme subunit alpha, mitochondrial and heterogeneous
nuclear ribonucleoprotein R were altered in abundance in
all treatments, whereas seven proteins were altered in
abundance in two drugs treatments (afatinib and neratinib
Table 2 21 proteins identified as differentially expressed between the neratinib treated BT474 cell line and the control following
label-free MS/MS analysis (Progenesis QI for proteomics)






P33121 Long-chain-fatty-acid–CoA ligase 1 2 113.74 5.94E-05 1.56 Neratinib
P40939 Trifunctional enzyme subunit alpha, mitochondrial 3 182.37 0.002972 1.51 Neratinib
P0C0S8 Histone H2A type 1 1 138.51 0.003414 3.51 Neratinib
P11021 78 kDa glucose-regulated protein 1 150.58 0.004321 2.87 Neratinib
P78527 DNA-dependent protein kinase catalytic subunit 7 374.79 0.007306 3.89 Neratinib
P0C0S5 Histone H2A.Z 1 151.7 0.007686 2.08 Neratinib
P09874 Poly [ADP-ribose] polymerase 1 5 283.35 0.008246 3.63 Neratinib
P19367 Hexokinase-1 2 130.52 0.009371 1.6 Neratinib
Q12906 Interleukin enhancer-binding factor 3 4 200.23 0.010842 1.59 Neratinib
O43390 Heterogeneous nuclear ribonucleoprotein R 2 116.88 0.011383 1.54 Neratinib
P36542 ATP synthase subunit gamma, mitochondrial 2 95.75 0.011427 1.52 Neratinib
P12956 X-ray repair cross-complementing protein 6 5 275.69 0.014417 1.94 Neratinib
P55084 Trifunctional enzyme subunit beta, mitochondrial 2 99.86 0.015542 1.52 Neratinib
Q99623 Prohibitin-2 2 121.16 0.015667 1.72 Neratinib
P42166 Lamina-associated polypeptide 2, isoform alpha 2 117 0.020737 1.65 Neratinib
P31943 Heterogeneous nuclear ribonucleoprotein H 1 135.7 0.026364 1.61 Neratinib
P80723 Brain acid soluble protein 1 2 112.84 0.029049 3.50 Neratinib
P50416 Carnitine O-palmitoyltransferase 1, liver isoform 2 135.07 0.029912 1.51 Neratinib
b
Q16643 Drebrin 2 153.59 2.19E-05 1.62 Control
P29966 Myristoylated alanine-rich C-kinase substrate 2 142.02 0.006012 1.59 Control
O95994 Anterior gradient protein 2 homolog 2 199.76 0.011444 1.56 Control
18 proteins were up regulated in the cells treated with neretinib (Table 2a) and three proteins were up regulated in the untreated cells (control) (Table 2a). *) Accession
number in the UniProt database; †) Peptides used for quantitation; ‡) MASCOT score. §) Indicates if the proteins were up regulated in the treated cells (neratinib) or in the
not treated cells (control)
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or neratinib and lapatinib). All these proteins were up-
regulated in response to the drugs treatment and are
generally involved in the fatty acid metabolism, DNA rep-
lication and glycolysis. Drebrin and myristoylated alanine-
rich C-kinase substrate were down-regulated in response
to neratinib and lapatinib treatment, both proteins are in-
volved in cell mobility.
Interestingly, within the 14 highlighted proteins a higher
number (11) were up-regulated in response to drug treat-
ments, these proteins are generally involved in the fatty
acid metabolism, DNA replication and glycolysis. It is
known that cancer cells are different from those of normal
cells, showing an increment of aerobic glycolysis, fatty acid
synthesis and glutamine metabolism that are needed for
proliferation. Cancer cells reprogram their metabolism in
order to satisfy their bioenergetic and biosynthetic re-
quirements. Increased aerobic glycolysis, fatty acid synthe-
sis and glutamine metabolism has been linked to
therapeutic resistance in cancer [23]. Several studies
highlighted that targeting cellular metabolism may im-
prove the response to cancer therapeutics and the com-
bination of chemotherapeutic drugs with cellular
metabolism inhibitors may represent a promising strategy
to overcome drug resistance in cancer therapy [23, 24]. In
the current study, an up-regulation of these proteins
was observed following drugs treatments and may be
potential targets to enhances therapeutic efficacy or
Table 3 16 proteins identified as differentially expressed between the lapatinib treated BT474 cell line and the control following
label-free MS/MS analysis (Progenesis QI for proteomics)






P78527 DNA-dependent protein kinase catalytic subunit 2 90.99 0.001596 3.82 Lapatinib
P40939 Trifunctional enzyme subunit alpha, mitochondrial 2 120.25 0.004413 1.66 Lapatinib
O43143 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 3 173.99 0.005281 1.57 Lapatinib
P45880 Voltage-dependent anion-selective channel protein 2 2 290.14 0.006264 1.69 Lapatinib
P11021 78 kDa glucose-regulated protein 1 148.58 0.009818 1.94 Lapatinib
P09874 Poly [ADP-ribose] polymerase 1 4 236.21 0.016504 4.24 Lapatinib
P82979 SAP domain-containing ribonucleoprotein 2 150.9 0.020883 1.60 Lapatinib
P42166 Lamina-associated polypeptide 2, isoform alpha 2 127.83 0.026885 1.94 Lapatinib
P62805 Histone H4 3 301.11 0.030621 2.10 Lapatinib
Q92522 Histone H1x 2 136.5 0.037085 1.74 Lapatinib
O43390 Heterogeneous nuclear ribonucleoprotein R 2 111.08 0.048527 1.74 Lapatinib
b
Q32MZ4 Leucine-rich repeat flightless-interacting protein 1 3 247.18 0.000444 1.62 Control
Q16643 Drebrin 2 149.36 0.001646 1.57 Control
P29966 Myristoylated alanine-rich C-kinase substrate 3 233.58 0.00855 1.64 Control
Q27J81 Inverted formin-2 2 130.65 0.0251 1.79 Control
P04155 Trefoil factor 1 2 126.83 0.026548 1.66 Control
11 proteins were up regulated in the cells treated with lapatinib (Table 3a) and five proteins were up regulated in the untreated cells (control) (Table 3a). *) Accession
number in the UniProt database; †) Peptides used for quantitation; ‡) MASCOT score. §) Indicates if the proteins were up regulated in the treated cells (lapatinib) or in the
not treated cells (control)
Fig. 1 Venn diagrams showing the number of identified proteins
with altered levels in response to afatinib, lapatinib or neratinib
treatment compared to control in BT474 cell line. The full lists of
proteins and the indication if they are up or down regulate are in
Tables 1, 2 and 3. Details of the proteins that were in common
between different comparisons are in Table 6
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combats drug resistance. The three proteins down-
regulated that were identified, are involved in stress re-
sponse, cell mobility and in different studies have been
shown to be up-regulated in tumours of varied origins
[25, 26]. In the current study, following drugs
treatments a down-regulation of these proteins was ob-
served, this could probably be due to several reasons
like alterations in cell morphology, modulation of the
immune response, toxicity of certain drugs [25, 26].
Few proteomics studies have been published to date char-
acterising an extensive drugs response in breast cancer. In a
previous study from our group [27], 67 proteins showed a
significant change in abundance in response to lapatinib in
SKBR3 cell line. Of these, inverted formin-2 was identified
in our study in the BT474 cell line treated with lapatinib
and was down-regulated in response to drug treatments in
both studies, whereas histone H2A type 1 and histone H3.1
were respectively identified as well in the neratinib and
afatinib treatment in BT474 cell line with a different abun-
dance pattern between the two studies. Heat shock cognate
71 kDa (HSC70) protein was identified in the neratinib
treatment of the SKBR3 and HCC1954 cell lines and was
up-regulated in response to drug treatments in both
studies.
Of the 17 proteins identified in the current study, some
were generally involved in the fatty acid metabolism, of
these, as previously mentioned, trifunctional enzyme sub-
unit alpha, mitochondrial was altered in abundance in all
three drugs treatments (lapatinib, neratinib or afatinib) in
BT474 and in SKBR3 cell line treated with neratinib.
Interestingly, the subunit beta was also identified in two
comparisons. In all treatments and cell lines both subunit
(alpha and beta) identified show a higher abundance in
the samples with treatments compared to the control.
This is to our knowledge, the first study to report differen-
tial abundance of trifunctional enzyme in relation to
Table 4 23 proteins identified as differentially expressed between the neratinib treated SKBR3 cell line and the control following
label-free MS/MS analysis (Progenesis QI for proteomics)






P13489 Ribonuclease inhibitor 4 310.49 0.000561 1.55 Neratinib
Q52LJ0 Protein FAM98B 2 90.26 0.000932 1.62 Neratinib
P49411 Elongation factor Tu, mitochondrial 3 201.31 0.001 1.52 Neratinib
P35232 Prohibitin 2 118.62 0.002224 1.64 Neratinib
Q8WUM4 Programmed cell death 6-interacting protein 2 105.79 0.004641 1.93 Neratinib
P00558 Phosphoglycerate kinase 1 2 201.12 0.00734 1.54 Neratinib
P27348 14-3-3 protein theta 1 151.89 0.008363 1.54 Neratinib
Q00610 Clathrin heavy chain 1 4 233.02 0.00934 1.70 Neratinib
P11177 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 2 96.98 0.010597 1.73 Neratinib
P50416 Carnitine O-palmitoyltransferase 1, liver isoform 2 126.77 0.010865 1.95 Neratinib
Q00325 Phosphate carrier protein, mitochondrial 2 106.39 0.011586 1.58 Neratinib
Q12931 Heat shock protein 75 kDa, mitochondrial 2 113.29 0.014076 1.77 Neratinib
P31040 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 2 100.63 0.017419 1.69 Neratinib
P40939 Trifunctional enzyme subunit alpha, mitochondrial 6 423 0.020319 1.71 Neratinib
Q13938 Calcyphosin 3 146.37 0.026178 1.98 Neratinib
P52209 6-phosphogluconate dehydrogenase, decarboxylating 3 152.09 0.035964 4.28 Neratinib
P05091 Aldehyde dehydrogenase, mitochondrial 6 351.3 0.045267 1.80 Neratinib
b
P11142 Heat shock cognate 71 kDa protein 6 500.28 0.003207 1.59 Control
P06703 Protein S100-A6 2 114.09 0.005483 1.72 Control
P39019 40S ribosomal protein S19 4 213.75 0.005586 1.8 Control
P63220 40S ribosomal protein S21 2 166.6 0.012224 2.43 Control
Q9UNZ2 NSFL1 cofactor p47 2 135.38 0.014751 1.51 Control
P16989 DNA-binding protein A 1 136.69 0.016278 1.53 Control
17 proteins were up regulated in the cells treated with neratinib (Table 4a) and six proteins were up regulated in the untreated cells (control) (Table 4b). *) Accession
number in the UniProt database; †) Peptides used for quantitation; ‡) MASCOT score. §) Indicates if the proteins were up regulated in the treated cells (neratinib) or in
the not treated cells (control)
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Table 5 46 proteins identified as differentially expressed between the neratinib treated HCC1954 cell line and the control following
label-free MS/MS analysis (Progenesis QI for proteomics)






P23141;Q9UKY3 Liver carboxylesterase 1 5 325.17 1.42E-06 42.37 Neratinib
Q07000 HLA class I histocompatibility antigen, Cw-15 alpha chain 3 177.55 0.000129 2.38 Neratinib
P19971 Thymidine phosphorylase 2 106.97 0.000245 24.47 Neratinib
P42224 Signal transducer and activator of transcription 1-alpha/beta 2 188.79 0.000677 3.17 Neratinib
P42330 Aldo-keto reductase family 1 member C3 1 197.69 0.004702 4.75 Neratinib
P16401 Histone H1.5 2 125.54 0.005291 1.91 Neratinib
Q9P2E9 Ribosome-binding protein 1 3 160.16 0.007391 1.75 Neratinib
P42166 Lamina-associated polypeptide 2, isoform alpha 2 181.9 0.009199 1.81 Neratinib
Q04828;P51857 Aldo-keto reductase family 1 member C1 1 154 0.009747 3.28 Neratinib
P00966 Argininosuccinate synthase 2 86.9 0.010658 3.2 Neratinib
P22314 Ubiquitin-like modifier-activating enzyme 1 11 865.85 0.010735 2.32 Neratinib
O00151 PDZ and LIM domain protein 1 2 125.36 0.011806 1.89 Neratinib
Q7Z406 Myosin-14 2 115.9 0.011847 1.84 Neratinib
P52209 6-phosphogluconate dehydrogenase, decarboxylating 7 460.35 0.012246 2.06 Neratinib
P11413 Glucose-6-phosphate 1-dehydrogenase 3 219.9 0.013282 3.65 Neratinib
P21333 Filamin-A 6 427.66 0.018947 1.90 Neratinib
P30101 Protein disulfide-isomerase A3 2 103.92 0.020008 1.56 Neratinib
O43175 D-3-phosphoglycerate dehydrogenase 2 130.68 0.021376 1.56 Neratinib
Q9BRT3 Migration and invasion enhancer 1 2 101.46 0.021575 1.61 Neratinib
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic 2 141.9 0.027272 1.83 Neratinib
O43707 Alpha-actinin-4 4 261.47 0.035891 1.96 Neratinib
P55327 Tumor protein D52 2 157.9 0.047466 8.1 Neratinib
b
P40926 Malate dehydrogenase, mitochondrial 4 253.25 0.000516 1.68 Control
P11142 Heat shock cognate 71 kDa protein 4 259.61 0.000586 1.65 Control
Q5VTE0 Putative elongation factor 1-alpha-like 3 2 133.8 0.001037 1.60 Control
O60506 Heterogeneous nuclear ribonucleoprotein Q 3 190.1 0.001168 1.78 Control
P19338 Nucleolin 8 505.63 0.001194 1.7 Control
P53999 Activated RNA polymerase II transcriptional coactivator p15 2 116.09 0.001608 1.54 Control
P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 6 388.91 0.001903 1.68 Control
P04083 Annexin A1 4 237.64 0.00211 1.67 Control
P04406 Glyceraldehyde-3-phosphate dehydrogenase 7 764.51 0.002767 1.75 Control
Q02790 Peptidyl-prolyl cis-trans isomerase FKBP4 4 220.23 0.003155 1.93 Control
P06748 Nucleophosmin 3 269.16 0.003382 1.78 Control
P00558 Phosphoglycerate kinase 1 5 330.19 0.004101 1.51 Control
P05120 Plasminogen activator inhibitor 2 2 125.82 0.004534 23.82 Control
P22234 Multifunctional protein ADE2 3 145.9 0.004729 1.75 Control
Q7KZF4 Staphylococcal nuclease domain-containing protein 1 2 103.98 0.005343 1.62 Control
P17301 Integrin alpha-2 2 123.5 0.006948 6.18 Control
P48643 T-complex protein 1 subunit epsilon 2 88.36 0.008121 1.67 Control
P25705 ATP synthase subunit alpha, mitochondrial 2 100.47 0.008561 1.62 Control
P16070 CD44 antigen 2 117.19 0.010439 3.57 Control
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HER2-positive response breast cancer. This protein is a
heterooctamer of four alpha- and four beta-subunits that
catalyses three steps in the beta-oxidation spiral of long
chain fatty acids. Deficiency of this proteins may cause,
vomiting, lethargy, irregular heart rate or sudden, unex-
pected death [28, 29]. It is known that the use of HER2-
targeted monoclonal antibodies like trastuzumab increase
the incidence of cardiac dysfunction. A significant reduc-
tion of this problem was firstly observed with the use of
HER2-targeted small-molecule inhibitors lapatinib and
then further decreased incidences evident with the use of
neratinib and afatinib second-generation tyrosine kinase
inhibitors [30]. The higher abundance of trifunctional en-
zyme subunit alpha, mitochondrial observed in the
current study following the use of novel HER2-targeted
therapies may suggest a role for this protein as a marker
for testing the toxicity of new HER2-inhibitors.
Heterogeneous nuclear ribonucleoproteins (hnRNPs) are
among the most abundant proteins in the eukaryotic
nucleus and comprise a family of RNA-binding proteins.
These proteins are involved in various steps of messenger
RNA (mRNA) biogenesis such as splicing and transport to
the cytoplasm [31, 32]. Deregulation of individual hnRNPs
was involved in tumour development and progression,
including inhibition of apoptosis, angiogenesis and cell
invasion [33]. In a study by Chen et al. [34] investigating
proteins that are associated with the resistance to paclitaxel
in human breast cancer cells, an overexpression of hnRNP
C1/C2 was associated with drug resistance. In other studies
about lung carcinogenesis a different hnRNP subtype
(A2/B1) has been proposed as a marker for early detection
[35, 36]. In the current study, different subtypes of this pro-
tein (D-like, U, H, Q and R) increased in abundance in one
or more drugs treatments (lapatinib, neratinib or afatinib)
in BT474 cell line. In particular the R subtypes was identi-
fied in all the treatments and may so be useful in predicting
an early cellular response in HER2-targetting therapies.
Lamina-associated polypeptide 2, isoform alpha (LAP2α)
was up-regulated in two cell lines (BT474 and HCC1954) in
response to neratinib and in response to lapatinib in BT474
cell line. LAP2α is one of six splice variants of the
mammalian LAP2 gene. LAP2α is a non-membrane protein
uniformly distributed throughout the nucleoplasm [37].
Several studies highlighted that this protein may be involved
in cancer development or may serve as useful diagnostic
and prognostic markers for some types of cancers [38–40].
However, the complex mechanisms of the involvement of
this protein in the genesis of the tumour remains to be elu-
cidated, and the contradictory reports in literature regarding
its potential role in cell proliferation highlight the need for
further work [38, 40]. The up-regulation observed in the
current study in the treated cells may provide useful infor-
mation to predict an early cellular response in HER2-
targetting therapies and this information could pave the way
to novel strategy to control the development of the cancer.
Proteins involved in the immune system process such as
HSC70 were also identified in this study. Stress-related
proteins are known as heat-shock proteins (HSP), their
role is to protect, preserve or recover the proper func-
tional conformation of proteins, they are divided into fam-
ilies according to their molecular weight. The 70 kDa HSP
family is composed of heat inducible proteins (HSP70)
Table 5 46 proteins identified as differentially expressed between the neratinib treated HCC1954 cell line and the control following
label-free MS/MS analysis (Progenesis QI for proteomics) (Continued)
P17987 T-complex protein 1 subunit alpha 2 113.87 0.015235 1.75 Control
P50990 T-complex protein 1 subunit theta 3 157.18 0.018346 2.22 Control
P08238 Heat shock protein HSP 90-beta 2 153.98 0.019861 3.16 Control
P48047 ATP synthase subunit O, mitochondrial 2 94.06 0.033513 2.54 Control
Q9UHD8 Septin-9 2 85.27 0.037332 1.61 Control
22 proteins were up regulated in the cells treated with neratinib (Table 5a) and 24 proteins were up regulated in the untreated cells (control) (Table 5b). *) Accession number
in the UniProt database; †) Peptides used for quantitation; ‡) MASCOT score. §) Indicates if the proteins were up regulated in the treated cells (neratinib) or in the not treated
cells (control)
Fig. 2 Venn diagrams showing the number of identified proteins
with altered levels in response to neratinib treatment compared to
control in BT474, SKBR3 and HCC1954 cell lines. The full lists of
proteins and the indication if they are up or down regulate are in
Tables 2, 4 and 5. Details of the proteins that were in common
between different comparisons are in Table 6
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Table 6 Proteins differentially expressed that have been identified in more than one comparisons between the identified proteins with altered levels in response to afatinib,













Trifunctional enzyme subunit alpha,
mitochondrial
fatty acid metabolism; carbohydrate metabolic process ↑ ↑ ↑ ↑ -
Heterogeneous nuclear ribonucleoprotein R DNA replication; RNA splicing; mRNA splicing;
protein metabolic process




process; cellular defense response
- ↑ ↑ - ↑
Phosphoglycerate kinase 1 Glycolysis ↓ - - ↑ ↓
Heterogeneous nuclear ribonucleoprotein H mRNA splicing ↑ ↑ - - -
Ubiquitin-like modifier-activating enzyme 1 coenzyme metabolic process; cellular protein
modification process; proteolysis; cell communication;
intracellular protein transport; nuclear transport
↓ - - - ↑
Interleukin enhancer-binding factor 3 apoptotic process; purine nucleobase metabolic
process; protein metabolic process; cell cycle; neurological
system process; response to stimulus; RNA localization
↑ ↑ - - -
Trifunctional enzyme subunit beta,
mitochondrial
protein acetylation ↑ ↑ - - -
Heterogeneous nuclear
ribonucleoprotein Q
DNA replication; RNA splicing; protein metabolic process;
cell cycle




immune system process; induction of apoptosis; DNA
repair; DNA recombination; protein phosphorylation;
response to stress
- ↑ ↑ - -
Drebrin cellular process; cellular component morphogenesis - ↓ ↓ - -
Myristoylated alanine-rich
C-kinase substrate




protein folding; response to stress; protein complex
biogenesis
- ↑ ↑ - -
Poly [ADP-ribose]
polymerase 1




cellular amino acid metabolic process; fatty acid
metabolic process
- ↑ - ↑ -
Heat shock cognate 71 kDa protein immune system process; protein folding; response to
stress; protein complex biogenesis
- - - ↓ ↓
6-phosphogluconate dehydrogenase,
decarboxylating
pentose-phosphate shunt - - - ↑ ↑
















that are expressed under cellular stress conditions, and
heat shock cognate proteins (HSC70) that are constitu-
tively expressed without any stress stimulation [41]. HSP
are overexpressed in patients with malignant tumours, the
expression of HSC70 has been reported on breast cancer
cells and the overexpression of HSP/HSC70 in chemore-
sistant cancer cells highlight these proteins as possible
clinical markers [25, 42, 43]. In the current study HSC70
was lower in abundance in the cell lines (SKBR3 and
HCC1954) treated with neratinib compared to the control.
It is known that that the inhibition of HSPs could be related
to the toxicity of certain drugs [43] highlighting the chemo-
therapeutic implications of this protein and the potentiality
as a marker to evaluate the potential importance of further
treatment options. Similar data were also obtained in re-
sponse to lapatinib in SKBR3 cell line in a previous study
from our group [27].
Taken together, our findings highlight several proteins
that are closely associated with early HER2-inhibitor re-
sponse, complementary studies need to be conducted to
validate the importance of our findings and this could
have implication for new strategies to improve the efficacy
of breast-cancer treatment.
Conclusion
In conclusion, we have identified several proteins that were
differentially expressed following exposure to clinically rele-
vant concentrations of different HER2-inhibitors drug treat-
ments in HER2-overexpressing breast cancer cell lines,
lapatinib, neratinib or afatinib in BT474 and in response to
neratinib treatment in two other cell lines (HCC1954 and
SKBR3). Of these, 14 proteins showed a similar abundance
pattern following different drug treatments and/or in differ-
ent cell lines. In particular, we have identified proteins like
trifunctional enzyme subunit alpha, mitochondrial; hetero-
geneous nuclear ribonucleoprotein R; LAP2α and HSC70
that were altered in abundance in three or more compari-
sons and may be strongly involved in an early treatment
response to HER2-inhibition. These may warrant further
investigation for example applying siRNA knockdown
protocols to reduce the protein levels in cells and to study
the functional consequences of their removal, this likely
could have implication for improve efficacy of HER2-
inhibitor based breast-cancer treatment.
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